The role of AXL in sorafenib-resistant HCC was first reported in a previous study, which showed that upregulation of AXL promoted the epithelial-to-mesenchymal transition pathway and thus increased the motility of sorafenib-resistant HCC cells [13]. The gene discussed is AXL; the disease is hepatocellular carcinoma.